Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Immunogen's Earnings: A Preview
 
Via Benzinga
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Analyst Ratings for Immunogen
 
Via Benzinga
Analyst Ratings for Immunogen
 
Via Benzinga
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
6 Analysts Have This to Say About Immunogen
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Immunogen
 
Via Benzinga
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
 
Via Benzinga
ImmunoGen Reports Recent Progress and 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
From ImmunoGen, Inc.
Via Business Wire
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday. 
Via Benzinga
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a... 
Via Benzinga
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.